Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2026-05-18 Sale | 2026-05-20 4:18 pm | Enliven Therapeutics Inc. | ELVN | Collins Helen Louise CHIEF MEDICAL OFFICER | 5,000 | $39.79 | $198,971 | 151,268 (Direct) | View |
| 2026-04-17 Sale | 2026-04-21 8:40 pm | Enliven Therapeutics Inc. | ELVN | Collins Helen Louise CHIEF MEDICAL OFFICER | 5,000 | $47.67 | $238,352 | 156,268 (Direct) | View |
| 2026-03-25 Sale | 2026-03-27 4:57 pm | Enliven Therapeutics Inc. | ELVN | Collins Helen Louise CHIEF MEDICAL OFFICER | 40,000 | $35.1 | $1,404,024 | 161,268 (Direct) | View |
| 2026-03-17 Sale | 2026-03-19 5:50 pm | Enliven Therapeutics Inc. | ELVN | Collins Helen Louise CHIEF MEDICAL OFFICER | 5,000 | $27.76 | $138,800 | 201,268 (Direct) | View |
| 2026-03-09 Sale | 2026-03-11 5:32 pm | Enliven Therapeutics Inc. | ELVN | Collins Helen Louise CHIEF MEDICAL OFFICER | 40,000 | $30.07 | $1,202,638 | 397,665 (Direct) | View |
| 2026-02-17 Sale | 2026-02-19 6:36 pm | Enliven Therapeutics Inc. | ELVN | Collins Helen Louise CHIEF MEDICAL OFFICER | 45,000 | $26.17 | $1,177,862 | 246,268 (Direct) | View |
| 2024-10-18 Sale | 2024-10-22 4:17 pm | Enliven Therapeutics Inc. | ELVN | Collins Helen Louise CHIEF MEDICAL OFFICER | 816 | $30 | $24,482 | 266,268 (Direct) | View |
| 2024-04-11 Sale | 2024-04-15 7:02 pm | Enliven Therapeutics Inc. | ELVN | Collins Helen Louise CHIEF MEDICAL OFFICER | 20,000 | $25.07 | $501,478 | 267,084 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2026-06-04 Option Award | 2026-06-04 6:30 pm | N/A 2036-06-03 | Kura Oncology Inc. | KURA | Collins Helen Louise Director | 35,000 | $0 | 35,000 (Direct) | View |
| 2026-05-18 Exercise | 2026-05-20 4:18 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Collins Helen Louise CHIEF MEDICAL OFFICER | 5,000 | $2.48 | 151,268 (Direct) | View |
| 2026-05-18 Exercise | 2026-05-20 4:18 pm | N/A 2031-06-17 | Enliven Therapeutics Inc. | ELVN | Collins Helen Louise CHIEF MEDICAL OFFICER | 5,000 | $0 | 151,268 (Direct) | View |
| 2026-04-17 Exercise | 2026-04-21 8:40 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Collins Helen Louise CHIEF MEDICAL OFFICER | 5,000 | $2.48 | 156,268 (Direct) | View |
| 2026-04-17 Exercise | 2026-04-21 8:40 pm | N/A 2031-06-17 | Enliven Therapeutics Inc. | ELVN | Collins Helen Louise CHIEF MEDICAL OFFICER | 5,000 | $0 | 156,268 (Direct) | View |
| 2026-03-25 Exercise | 2026-03-27 4:57 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Collins Helen Louise CHIEF MEDICAL OFFICER | 40,000 | $2.48 | 161,268 (Direct) | View |
| 2026-03-25 Exercise | 2026-03-27 4:57 pm | N/A 2031-06-17 | Enliven Therapeutics Inc. | ELVN | Collins Helen Louise CHIEF MEDICAL OFFICER | 40,000 | $0 | 161,268 (Direct) | View |
| 2026-03-17 Exercise | 2026-03-19 5:50 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Collins Helen Louise CHIEF MEDICAL OFFICER | 5,000 | $2.48 | 201,268 (Direct) | View |
| 2026-03-17 Exercise | 2026-03-19 5:50 pm | N/A 2031-06-17 | Enliven Therapeutics Inc. | ELVN | Collins Helen Louise CHIEF MEDICAL OFFICER | 5,000 | $0 | 201,268 (Direct) | View |
| 2026-03-09 Exercise | 2026-03-11 5:32 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Collins Helen Louise CHIEF MEDICAL OFFICER | 40,000 | $2.48 | 397,665 (Direct) | View |
| 2026-03-09 Exercise | 2026-03-11 5:32 pm | N/A 2031-06-17 | Enliven Therapeutics Inc. | ELVN | Collins Helen Louise CHIEF MEDICAL OFFICER | 40,000 | $0 | 397,665 (Direct) | View |
| 2026-02-17 Exercise | 2026-02-19 6:36 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Collins Helen Louise CHIEF MEDICAL OFFICER | 45,000 | $2.48 | 246,268 (Direct) | View |
| 2026-02-17 Exercise | 2026-02-19 6:36 pm | N/A 2031-06-17 | Enliven Therapeutics Inc. | ELVN | Collins Helen Louise CHIEF MEDICAL OFFICER | 45,000 | $0 | 246,268 (Direct) | View |
| 2026-02-12 Option Award | 2026-02-17 7:47 pm | N/A 2036-02-12 | Enliven Therapeutics Inc. | ELVN | Collins Helen Louise CHIEF MEDICAL OFFICER | 175,000 | $0 | 175,000 (Direct) | View |
| 2025-06-05 Option Award | 2025-06-06 4:24 pm | N/A 2035-06-05 | IO Biotech Inc. | IOBT | Collins Helen Louise Director | 35,144 | $0 | 35,144 (Direct) | View |
| 2025-06-05 Option Award | 2025-06-06 4:05 pm | N/A 2035-06-04 | Kura Oncology Inc. | KURA | Collins Helen Louise Director | 28,500 | $0 | 28,500 (Direct) | View |
| 2025-02-06 Option Award | 2025-02-10 5:25 pm | N/A 2035-02-06 | Enliven Therapeutics Inc. | ELVN | Collins Helen Louise CHIEF MEDICAL OFFICER | 171,000 | $0 | 171,000 (Direct) | View |
| 2024-10-18 Exercise | 2024-10-22 4:17 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Collins Helen Louise CHIEF MEDICAL OFFICER | 816 | $2.48 | 266,268 (Direct) | View |
| 2024-10-18 Exercise | 2024-10-22 4:17 pm | N/A 2031-06-17 | Enliven Therapeutics Inc. | ELVN | Collins Helen Louise CHIEF MEDICAL OFFICER | 816 | $0 | 266,268 (Direct) | View |
| 2024-06-05 Option Award | 2024-06-07 4:30 pm | N/A 2034-06-04 | Kura Oncology Inc. | KURA | Collins Helen Louise Director | 26,000 | $0 | 26,000 (Direct) | View |
| 2024-06-06 Option Award | 2024-06-07 4:12 pm | N/A 2034-06-06 | IO Biotech Inc. | IOBT | Collins Helen Louise Director | 45,642 | $0 | 45,642 (Direct) | View |
| 2024-04-11 Exercise | 2024-04-15 7:02 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Collins Helen Louise CHIEF MEDICAL OFFICER | 20,000 | $2.48 | 267,084 (Direct) | View |
| 2024-04-11 Exercise | 2024-04-15 7:02 pm | N/A 2031-06-17 | Enliven Therapeutics Inc. | ELVN | Collins Helen Louise CHIEF MEDICAL OFFICER | 20,000 | $0 | 267,084 (Direct) | View |
| 2024-02-13 Option Award | 2024-02-15 8:46 pm | N/A 2034-02-12 | Enliven Therapeutics Inc. | ELVN | Collins Helen Louise CHIEF MEDICAL OFFICER | 185,000 | $0 | 185,000 (Direct) | View |
| 2023-11-15 Option Award | 2023-11-17 4:47 pm | N/A 2033-11-15 | IO Biotech Inc. | IOBT | Collins Helen Louise Director | 64,238 | $0 | 64,238 (Direct) | View |
| 2023-05-31 Option Award | 2023-06-02 4:45 pm | N/A 2033-05-30 | Kura Oncology Inc. | KURA | Collins Helen Louise Director | 26,000 | $0 | 26,000 (Direct) | View |
| 2023-04-04 Option Award | 2023-04-06 8:32 pm | N/A 2033-04-04 | Enliven Therapeutics Inc. | ELVN | Collins Helen Louise Chief Medical Officer | 206,000 | $0 | 206,000 (Direct) | View |
| 2023-02-23 Option Award | 2023-02-27 9:32 pm | N/A 2031-06-17 | Enliven Therapeutics Inc. | ELVN | Collins Helen Louise Chief Medical Officer | 287,084 | $0 | 287,084 (Direct) | View |
| 2022-06-21 Option Award | 2022-06-23 4:54 pm | N/A 2032-06-20 | Kura Oncology Inc. | KURA | Collins Helen Louise Director | 23,000 | $0 | 23,000 (Direct) | View |
| 2021-07-28 Option Award | 2021-07-29 5:17 pm | N/A 2031-07-27 | Kura Oncology Inc. | KURA | Collins Helen Louise Director | 65,166 | $0 | 65,166 (Direct) | View |